Kyverna Therapeutics Statistics
Share Statistics
Kyverna Therapeutics has 43.17M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 43.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 7.11K |
| FTD / Avg. Volume | 1.91% |
Short Selling Information
The latest short interest is 2.41M, so 5.59% of the outstanding shares have been sold short.
| Short Interest | 2.41M |
| Short % of Shares Out | 5.59% |
| Short % of Float | 12.91% |
| Short Ratio (days to cover) | 7.14 |
Valuation Ratios
The PE ratio is -334.77 and the forward PE ratio is -1.33.
| PE Ratio | -334.77 |
| Forward PE | -1.33 |
| PS Ratio | 0 |
| Forward PS | 28.6 |
| PB Ratio | 410.94 |
| P/FCF Ratio | -381.07 |
| PEG Ratio | n/a |
Enterprise Valuation
Kyverna Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.05 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.6 |
| Cash Flow / Debt | -17.95 |
| Interest Coverage | -333.72 |
Financial Efficiency
Return on equity (ROE) is -1.23% and return on capital (ROIC) is -107.12%.
| Return on Equity (ROE) | -1.23% |
| Return on Assets (ROA) | -0.8% |
| Return on Capital (ROIC) | -107.12% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -628.81K |
| Employee Count | 96 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Kyverna Therapeutics 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 4.98 |
| 200-Day Moving Average | 11.33 |
| Relative Strength Index (RSI) | 43.29 |
| Average Volume (20 Days) | 372.11K |
Income Statement
In the last 12 months, Kyverna Therapeutics had revenue of $0 and earned -$60.37M in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | -1.71M |
| Operating Income | -62.41M |
| Net Income | -60.37M |
| EBITDA | -58.47M |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $34.65M in cash and $9.08M in debt, giving a net cash position of $25.57M.
| Cash & Cash Equivalents | 34.65M |
| Total Debt | 9.08M |
| Net Cash | 25.57M |
| Retained Earnings | -136.04M |
| Total Assets | 339.20M |
| Working Capital | 294.39M |
Cash Flow
In the last 12 months, operating cash flow was -$52.41M and capital expenditures -$621.00K, giving a free cash flow of -$53.03M.
| Operating Cash Flow | -52.41M |
| Capital Expenditures | -621.00K |
| Free Cash Flow | -53.03M |
| FCF Per Share | -0.08 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KYTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -27.85% |
Analyst Forecast
The average price target for KYTX is $24, which is 444.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 444.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 2.34 |
| Piotroski F-Score | 2 |